首页> 外文期刊>Human Pathology >J chain and myocyte enhancer factor 2B are useful in differentiating classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
【24h】

J chain and myocyte enhancer factor 2B are useful in differentiating classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

机译:J链和肌细胞增强剂因子2b可用于区分从结节淋巴细胞主要霍奇金淋巴瘤和原发性纵隔大b细胞淋巴瘤的典型霍奇金淋巴瘤

获取原文
获取原文并翻译 | 示例
           

摘要

Summary Although most classical Hodgkin lymphomas (CHLs) are easily distinguished from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) and primary mediastinal large B-cell lymphoma (PMBL), cases with significant CD20 expression cause diagnostic confusion. Although the absence of OCT-2 and BOB.1 are useful in these circumstances, a variable proportion of CHLs are positive for these antigens. We investigated the utility of J chain and myocyte enhancer factor 2B (MEF2B) in the diagnosis of CHL; NLPHL; PMBL; T-cell/histiocyte-rich large B-cell lymphoma (TCRLBL); and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and CHL, compared with OCT-2 and BOB.1. J chain and MEF2B highlighted lymphocyte predominant (LP) cells in 20/20 (100%) NLPHLs and were negative in 43/43 (100%) CHLs. Fourteen of 15 (93%) PMBLs and 4/4 (100%) TCRLBLs were MEF2B positive, whereas 67% of PMBLs and 50% of TCRLBLs were J chain positive. Three of 3 B-cell lymphomas, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and CHL, were negative for J chain and MEF2B. J chain and MEF2B were 100% sensitive and specific for NLPHL versus CHL. MEF2B was 100% sensitive and 98% specific for PMBL versus CHL. Whereas loss of OCT-2 and/or BOB.1 expression had a sensitivity of only 86% and specificity of 100% for CHL versus NLPHL, PMBL, and TCRLBL, lack of both J chain and MEF2B expression was 100% sensitive and 97% specific. J chain and MEF2B are highly sensitive and specific markers of NLPHL versus CHL; are particularly useful in highlighting LP cells; and, with rare exception, are of greater utility than OCT-2 and BOB.1 in differentiating CHL from NLPHL and other large B-cell lymphomas. Highlights " J chain and MEF2B highlight LP cells in NLPHL with little additional staining. " J chain and MEF2B are highly sensitive and specific markers of NLPHL versus CHL. " OCT-2 and BOB.1 stains are less sensitive in distinguishing NLPHL from CHL.
机译:发明内容尽管大多数古典霍奇金淋巴瘤(CHLS)很容易与结节淋巴细胞主要霍格金淋巴瘤(NlPH1)和原发性纵隔大B细胞淋巴瘤(PMBL),但具有显着的CD20表达的病例导致诊断混淆。虽然在这种情况下没有10℃和鲍勃1的缺失是有用的,但是CHL的可变比例为这些抗原。我们调查了J链和肌细胞增强子因子2b(MEF2b)在CHL的诊断中的效用; nlphl; PMBL; T细胞/组织细胞富含大型B细胞淋巴瘤(TCRLBL);和B细胞淋巴瘤,无分配的,与弥漫性大B细胞淋巴瘤和CHL之间的具有中间体,与OCT-2和BOB.1相比。 J链和MEF2B在20/20(100%)Nlphl中突出显示淋巴细胞主要(LP)细胞,并在43/43(100%)CHL中为阴性。 15个(93%)PMBL和4/4(100%)TCRLBL的14个是MEF2B阳性,而67%的PMBL和50%的TCRLBL是J链阳性。 3个B细胞淋巴瘤中的三种,不可划分的,具有弥漫性大B细胞淋巴瘤和CHL之间的中间体的特征对于J链和MEF2B是阴性的。 J链和MEF2B为100%敏感和特定的NLPHL与CHL。 MEF2B为100%敏感,98%针对PMBL与CHL特异性。虽然OCT-2和/或烟棒1的损失的敏感性仅为86%,并且CHL与Nlphl,PMBL和TCRLBL的特异性为100%,缺乏J链和MEF2B表达为100%敏感和97%具体的。 J链和MEF2B是NLPHL与CHL的高度敏感和特异性标记;在突出显示LP细胞中特别有用;并且,对于罕见的例外,在将CHL与其他大B细胞淋巴瘤中的CHL分化为OCT-2和BOB.1,具有罕见的效用。突出显示“J Chain和MeF2B突出显示NLPHL中的LP细胞,几乎没有额外的染色。”J Chain和MEF2B是NLPHL与CHL的高度敏感和特定的标记。 “Oct-2和Bob1污渍在区分Nlphl从CHL中的敏感性不太敏感。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号